A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01) Meeting Abstract
| Authors: | Li, B. T.; Meric-Bernstam, F.; Puvvada, S. D.; Rowbottom, J.; Jolliffe, D.; Gustavson, M.; Mendoza-Naranjo, A. |
| Abstract Title: | A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01) |
| Meeting Title: | 2021 ASCO Annual Meeting |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 39 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2021 Jun 4-8 |
| Meeting Location: | Virtual |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2021-05-20 |
| Language: | English |
| ACCESSION: | WOS:000708120306241 |
| DOI: | 10.1200/JCO.2021.39.15_suppl.TPS3162 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS3162 -- Source: Wos |
